Business Context and Reporting Period
Company: Altimmune, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 16, 2017
Event: Entry into a Material Definitive Agreement for a private placement offering of Series B Convertible Preferred Stock and Warrants.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $14.7 million (prior to fees and expenses).
- Securities Issued:
- 15,656 shares of Series B Convertible Preferred Stock (initial stated value $1,000 per share).
- Warrants to purchase 2,345,427 shares of Common Stock.
- Conversion/Exercise Price: $2.67 per share of Common Stock.
- Placement Agent Fee: 7.0% of gross proceeds (Piper Jaffray & Co.).
- Expense Reimbursement: Up to $150,000 for out-of-pocket fees and expenses.
- Liquidity Impact: Proceeds intended to fund operations; closing expected on or about August 21, 2017.
Material Changes and Structural Terms
This filing represents a significant capital raise and changes the company's capital structure. Key structural terms include:
- Amortization Schedule: The Preferred Stock is subject to monthly redemption (amortization) starting December 15, 2017, with approximately 1/9th of the stock redeemed monthly until the Maturity Date.
- Payment Flexibility: The Company may elect to pay the Monthly Amortization Amount in cash or shares of Common Stock based on specific pricing formulas.
- Anti-Dilution Protection: Both the Preferred Stock and Warrants include full ratchet anti-dilution adjustments if equity is issued below the conversion/exercise price.
- Triggering Events: In the event of specific negative events (e.g., suspension of trading), holders may demand redemption at 125% of stated value or convert at a discounted price (75% of VWAP).
- Stockholder Approval: Required by October 31, 2017, to satisfy Nasdaq Listing Rules regarding the issuance of Common Stock upon conversion or exercise.
Guidance, Outlook, and Restrictions
- Lock-Up Agreement: Executive officers and directors (owning ~43% of outstanding Common Stock) agreed not to sell or hedge shares for one year from the Closing Date or until the Preferred Stock is no longer outstanding.
- Voting Agreement: Stockholders owning ~39% of Common Stock agreed to vote in favor of the required stockholder approval.
- Issuance Restriction: Until 60 days after stockholder approval or May 1, 2018, the Company is restricted from offering or selling additional equity or equity-linked securities.
- Outlook: The filing does not provide specific operational guidance or revenue forecasts, focusing solely on the financing transaction.
Investor Verification Checklist
- Verify the closing of the transaction and receipt of the $14.7 million gross proceeds.
- Monitor the Company's ability to obtain Requisite Stockholder Approval by October 31, 2017.
- Review the Certificate of Designations for specific "Triggering Events" that could accelerate redemption or dilution.
- Assess the impact of the monthly amortization payments on future cash flow or share count dilution.
- Confirm the final net proceeds after deducting the 7% placement fee and estimated expenses.